Sleep during oncological treatment – a systematic review and meta-analysis of associations with treatment response, time to progression and survival

dc.contributor.authorStrøm, Louise
dc.contributor.authorDanielsen, Josefine T.
dc.contributor.authorAmidi, Ali
dc.contributor.authorEgusquiza, Ana Lucia Cardenas
dc.contributor.authorWu, Lisa M.
dc.contributor.authorZachariae, Robert
dc.contributor.departmentDepartment of Psychology
dc.date.accessioned2026-10-09T10:14:06Z
dc.date.available2026-10-09T10:14:06Z
dc.date.issued2022-04-19
dc.description.abstractIntroduction: Disrupted sleep and sleep-wake activity are frequently observed in cancer patients undergoing oncological treatment. These disruptions are often associated with aggravated symptom burden and diminished health-related quality of life that in turn may compromise treatment adherence and, thus, effectiveness. In addition, disrupted sleep has been linked to carcinogenic processes, which ultimately could result in worse prognostic outcomes. Aims: Our aim was to systematically review and conduct a meta-analysis of studies examining the associations between sleep and sleep-wake activity and prognostic outcomes in cancer patients undergoing oncological treatment. Methods: A comprehensive systematic search of English language papers was undertaken in June 2020 using PubMed, The Cochrane Library, and CINAHL. Two reviewers independently screened 4,879 abstracts. A total of 26 papers were included in the narrative review. Thirteen papers reporting hazard ratios reflecting associations between a dichotomized predictor variable (sleep) and prognostic outcomes were subjected to meta-analysis. Results: Nineteen of the 26 eligible studies on a total of 7,092 cancer patients reported associations between poorer sleep and poorer response to treatment, shorter time to progression, and/or reduced overall survival, but were highly heterogeneous with respect to the sleep and outcome parameters investigated. Meta-analysis revealed statistically significant associations between poor self-reported sleep and reduced overall survival (HR = 1.33 [95% CI 1.09-1.62], k = 11), and shorter time to progression (HR = 1.40 [95% CI 1.23-1.59], k = 3) and between poor objectively assessed sleep and reduced overall survival (HR = 1.74 [95% CI 1.05-2.88], k = 4). Conclusion: The current findings indicate that disturbed sleep during treatment may be a relevant behavioral marker of poor cancer prognosis. The limited number of studies, the common use of single item sleep measures, and potential publication bias highlight the need for further high quality and longitudinal studies.en
dc.description.versionPeer revieweden
dc.format.extent3161898
dc.format.extent
dc.identifier.citationStrøm, L, Danielsen, J T, Amidi, A, Egusquiza, A L C, Wu, L M & Zachariae, R 2022, 'Sleep during oncological treatment – a systematic review and meta-analysis of associations with treatment response, time to progression and survival', Frontiers in Neuroscience, vol. 16, 817837. https://doi.org/10.3389/fnins.2022.817837en
dc.identifier.doi10.3389/fnins.2022.817837
dc.identifier.issn1662-4548
dc.identifier.other251176570
dc.identifier.other62a90259-0488-4c65-ae8c-5e72fc8613e7
dc.identifier.otherORCID: /0000-0003-2241-9905/work/174438953
dc.identifier.other85129239272
dc.identifier.other35516799
dc.identifier.other85129239272
dc.identifier.urihttps://hdl.handle.net/20.500.11815/8597
dc.language.isoen
dc.relation.ispartofseriesFrontiers in Neuroscience; 16()en
dc.relation.urlhttps://pure.au.dk/portal/en/publications/055a7014-16a6-4f57-b70f-9cda831c93ceen
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.titleSleep during oncological treatment – a systematic review and meta-analysis of associations with treatment response, time to progression and survivalen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/articleen

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Nafn:
fnins-16-817837.pdf
Stærð:
3.02 MB
Snið:
Adobe Portable Document Format